Trial
NCT02092909
Phase 1/2 Dose Escalation Study in Patients With Relapsed or Refractory Waldenstrom's Macroglobulinemia
Phase ITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Idera Pharmaceuticals, Inc.
Collaborators
—
Condition
Waldenstrom's Macroglobulinemia
Intervention
IMO-8400
Why stopped
Lack of efficacy
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-09-10